Abstract
There is no doubt that hypercholesterolemia is associated with an increased risk of coronary heart disease. Evidence for this in man has been derived from various sources. Clinicians have long recognized that certain forms of hypercholesterolemia are familial and are often associated with premature vascular disease. In numerous retrospective studies higher lipid levels were observed in subjects with a history of myocardial infarction when compared with control subjects, especially in the younger age groups. The most impressive evidence, however, is derived from the results of prospective population studies (1). Of these the Framingham study is probably the best known. In this study, it was found for example, that in males 34 to 44 years of age, a cholesterol level over 265 mg/100 ml is associated with a five times greater risk that coronary heart disease will develop than levels below 220 mg/100 ml.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arthur, J. B., et alTrial of clofìbrate in the treatment of ischemic heart disease. Br. Med. Jr., 2:767, 1971.
Brown, M. S. and Goldstein, J. L. Expression of the familial hypercholesterolemia gene in heterozygotes: Mechanism for a dominant disorder in man. Science, 85:61, 1974.
Carlson, L. A. and Böttiger, L. E. Ischaemic heart disease in relation to fasting values of plasma triglycerides and cholesterol. Lancet, 1:865, 1972.
Cornfield, J. and Mitchell, S. Selected risk factors in coronary disease. Possible intervention effects. Arch. Environ. Health, 19:382, 1969.
Cornfield, J. Halperin, M., and Mitchell, S. Effect of diet on coronary heart disease mortality. Lancet, 2:438, 1973.
The Coronary Drug Project. Findings leading to discontinuation of the 2.5 mg/day estrogen group. J.A.M.A., 226:654, 1973.
The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. J.A.M.A., 220:996, 1972.
The Coronary Drug Project. Initial findings leading to modifications of its research protocol. J.A.M.A., 214:1303, 1970.
Feinstein, A. R. The clofìbrate trials: Another dispute about contratrophic therapy. Clin. Pharmacol. Ther., 13:953, 1972.
Fredrickson, D. S. and Levy, R. I. Familial hyperlipoproteinemia. InStanbury, J. B., Wyngaarden, J. B., and Fredrickson, D. S. eds. Metabolic Basis of Inherited Disease, 3rdEd. New York, 1972, pp. 545–614.
Fredrickson, D. S., Levy, R. I., Jones, E., Bonnell, M., and Ernst, N. The Dietary Management of Hyperlipoproteinemia: A Handbook for Physicians. Washington, D.C., U.S. Dept. of Health, Education and Welfare, Public Health Service, U.S. Government Printing Office, 1970.
Fredrickson, D. S., Levy, R. I., and Lees, R. S. Fat transport in lipoproteins-an integrated approach to mechanisms and disorders. N. Engl. J. Med., 276:32, 94, 148, 215, 273, 1967.
Goldstein, J. L., Hazzard, W. R., Schrott, H. G., Bierman, E. L., and Motulsky, A. G. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J. Clin. Invest., 52:1533, 1973.
Kannell, W. B., Castelli, W. P., Gordon, T., and McNamara, P. M. Serum cholesterol, lipoproteins and the risk of coronary heart disease. Ann. Intern. Med., 74:1, 1971.
Krasno, L. R. and Kidera, G. J. Clofìbrate in coronary heart disease. Effects on morbidity and mortality. J.A.M.A., 219:845, 1972.
Levy, R. I., Bonnell, M., and Ernst, N. D. Dietary management of hyperlipoproteinemia. J. Am. Dietetic Assoc., 58:406, 1971.
Levy, R. I. and Rifkind, B. M. Lipid lowering drugs and hyperlipidemia. Drugs, 6:12, 1973.
Miettinen, M., Turpeinen, O., Karvonen, M. J., Elosuo, R,, and Paavlainen, E. Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes. A twelve-year clinical trial in men and women. Lancet, 1:835, 1972.
National Heart and Lung Institute Task Force on Arteriosclerosis. Washington, D.C., U.S. Dept. of Health, Education and Welfare, Public Health Service, U.S. Government Printing Office, 1971.
Oliver, M. F., et al. Ischemic heart disease: A secondary prevention trial using clofibrate. Br. Med. J., 2:775, 1971.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1976 Springer-Verlag New York Inc.
About this chapter
Cite this chapter
Rifkind, B.M., Levy, R.I. (1976). Hyperlipidemia and Vascular Disease. In: Chung, E.K. (eds) Controversy in Cardiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-86000-3_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-86000-3_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-86002-7
Online ISBN: 978-3-642-86000-3
eBook Packages: Springer Book Archive